P ertussis is a respiratory tract disease, most commonly caused by the gram-negative bacterium Bordetella pertussis. it occurs epidemically and endemically with irregular geographical and seasonal variability and it affects patients at any age as studies from various parts of the world have shown. [1] [2] [3] [4] However, the disease is most serious in infants where it can cause complications such as pneumonia, cyanosis, apnea, cerebral convulsions and encephalopathy. 4, 5 Since the introduction of pertussis whole cell vaccines and their implementation in national immunization programs for children in the late 1950s, followed by a switch to acellular pertussis component vaccines in the 1990s, many countries have experienced a decrease in reported cases and a shift in age distribution, with relatively more cases occurring not only in adolescents and adults but also in infants <6 (−12) months of age. 6 today, many countries have established surveillance systems to monitor frequency and severity of pertussis as a basis for assessing the need for adaptations of national immunization schedules. 7 With this background, in addition to a continuous and ongoing ambulatory pertussis sentinel program, 8 we monitored hospitalizations due to pertussis via the Swiss Pediatric Surveillance unit (SPSu) for the duration 2006-2010. the aim of this prospective surveillance was to assess the burden of pertussis in the most vulnerable population and to describe the characteristics of pertussis in hospitalized patients, that is, age-specific numbers and rates of hospitalization due to pertussis, clinical presentations, pertussis vaccination status and source of infection. Here, we report the findings of this project that contributed to the introduction of pertussis immunizations for all adolescents (in 2013), 9 young adults (in 2012) 10 and pregnant women (in 2013) 9 in Switzerland.
METHODS

Swiss Pediatric Surveillance Unit
the SPSu was established in 1995 to assess the epidemiology of selected childhood diseases leading to hospitalization in any of the pediatric hospitals or pediatric units in general hospitals in Switzerland. the study period for pertussis was april 1, 2006, to March 31, 2010. each month, cases of pertussis were actively reported to SPSu by a standardized reporting form. Following each report of a case, a standardized questionnaire was sent by the central SPSu office to the reporting institution to obtain details regarding patient history and course of the disease during (but not beyond) hospitalization. the following items were obtained: date of hospital admission and date of discharge; date of birth, gender, birth weight, gestational age, nationality and place of residence; pertussis immunization status (vaccine name, number of doses in total and dates of administration); reason for hospitalization, onset of first signs or symptoms, onset and end of cough, characteristics of cough (checklist including paroxysms, apnea, etc.) and disease (occurrence of fever, sleeping disturbances, etc.); complications during course of disease; microbiologic laboratory tests and results; details on treatment (intensive care unit, respiratory support, antibiotics, etc.) and details on contact to persons with cough illnesses compatible with pertussis within and outside the patient's household within 3 weeks of onset of disease. the questionnaire is available from the authors on request.
Performance of SPSu projects is in accordance with data protection guidelines of all participating pediatric units.
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by culture or polymerase chain reaction (PCr)]. these laboratory tests were performed regionally according to the various pediatric institutions' practices.
Data Analyses and Statistics
Questionnaires were sent to the coprinicipal investigator (u.H.) who checked them for completeness and plausibility, followed by queries to the reporter if necessary. after data clarification, questionnaires were sent in monthly bulks to the coinvestigators at the Swiss Federal Office of Public Health where all data were entered in an excel database. after conclusion of the study and a grace period for collection of outstanding questionnaires, the database was transferred to the coprincipal investigator's institution in april 2011 for analyses (u.H. and d.W.). this report is based on all cases of clinical or laboratory-confirmed B. pertussis infections.
to characterize the pediatric patients in this study, we performed descriptive statistical analyses. Frequencies, medians and percentages of aggregated patient groups were determined and the clinical details of all patients were noted and stratified. data were managed and analyzed using Statistical Package for Social Sciences software (version: iBM SPSS Statistics 20, iBM Switzerland, Zurich, Switzerland).
RESULTS
during the study period, there were 33 (2010) to 36 (2006) pediatric units or hospitals in Switzerland, all of which participate in the SPSu projects. Compliance with return of the monthly reporting forms was 100% during the whole study period.
a total of 173 cases of "pertussis" were reported to SPSu and questionnaires could be obtained from 159 cases. Of these, 29 were excluded for the following reasons: no laboratory confirmation of B. pertussis by either PCr or culture and clinical case definition not fulfilled (n = 22), PCr positive for B. parapertussis and negative PCr and/or culture for B. pertussis (n = 5) and not hospitalized (n = 2). the remaining 130 patients (54 females, 42%) are the basis of the following analyses in this report. all 130 patients had nasopharyngeal specimen (nPS) taken for PCr analyses: 121 (93%) had clinically and PCr-confirmed B. pertussis infections, 4 (3%) had PCr-confirmed B. pertussis infections but the clinical case definition was not fulfilled at the time of discharge from hospital (duration of cough <14 days) and 5 (4%) fulfilled the clinical case definition but were PCr negative. in 5 patients, nPS was tested by PCr and culture: B. pertussis was grown from 2 nPS and PCr was positive in all 5 nPS.
age of patients on day of hospitalization ranged from 18 days to 13.5 years with a median of 11 weeks. the great majority of patients were infants (117 of 130, 90%, table 1). the mean annual hospitalization rate for pertussis was 2.6 per 100,000 children <16 years of age and 38.8 per 100,000 in infants (<1 year). Main reasons for hospitalization were severe cough and/or feeding difficulties. the average duration of the first hospitalization was 8.8 days (median 6.0 days) and it correlated negatively with patient age (table 1) . Of 130 patients, 11 (8%) were readmitted to hospital once and 2 patients (2%) were readmitted twice for the same cough episode. risk of readmission decreased sharply with increasing age: 8 (16%) of 50 patients <2 months of age were readmitted compared with 3 (6%) of 54 patients 2-5 months of age and none (0%) of 26 patients ≥6 months of age.
Signs and symptoms of pertussis by age categories are presented in table 2 and most frequent complications in table 3 . Overall, 35 (27%) patients received intensive care for 1-28 days duration (2-16 days in newborns) with highest proportions among newborns and 1-month olds (80% and 35%, respectively, compared with 11% for ≥3-month-old patients). Five patients required mechanical intubation. One 21-month-old unvaccinated girl with underlying trisomy 21 died on day 6 of hospitalization due to pneumonia.
the suspected source of infection was known in 79 (61%) of patients (table 4) . Of the known sources, the great majority (n = 76; 96%) were close contact persons with almost equal distribution of children (siblings) and adults (mainly parents). in the 7 newborns with known probable sources of infection, an adult was always involved. Pertussis immunization status was known in 128 (98%) of 130 patients and 83 of them (65%) were unimmunized including 55 cases (43%) too young to be vaccinated (<2 months of age at symptoms onset). Of the 45 immunized patients, the number of pertussis vaccine doses was known in 39 patients: 31 patients (28 of them <6 months of age) had received a single dose and 19 of them had received it ≥14 days before onset of pertussis; 6 patients (4 of them <6 months of age and 2 were 6-11 months of age) had received 2 doses; 1 patient (12.4 years of age) had received 3 doses (with the third dose at 6 months of age) and 1 patient (4 years of age) had received 4 doses (fourth dose at 18 months of age). this was the only patient with a complete primary series (3 doses) and an age-appropriate immunization status.
antibiotic treatment was administered to 120 (92%): clarithromycin (n = 115), azithromycin (n = 4) or erythromycin (n = 1). Of these patients, 8 had received 1 or 2 other antibiotics in addition to the macrolide and 10 children (including 8 infants) did not receive any antibiotic.
DISCUSSION
We prospectively assessed rates and characteristics of pertussis leading to hospitalization in the pediatric population of Switzerland for 4 years and found highest rates of disease in newborns and young infants. although prospective nationwide studies similar to our study, on hospitalizations due to pertussis, are sparse and limited to infants, 11, 12 retrospective studies from other countries which (like our surveillance) included older children have also shown that disease was most frequent and severe in infants.
2,13,14 despite this uniform observation, specific rates of hospitalization due to pertussis in infants vary considerably between these studies with values as high as >800 per 100,000 2 and in the same range as ours (approximately 40) in australia, the united States and germany in recent years.
3,12,13 in a 10-year study, from a French pediatric hospital network, where hospitalizations due to pertussis in infants <6 months of age were monitored, yearly incidence rates per 100,000 were highest in infants <3 months of age with an average of 276.
11
Clinical signs and symptoms of patients (eg, occurrence of paroxysmal cough in 128 of 130 patients) were highly suggestive of pertussis and apparently typical pertussis was a rule rather than an exception in our study. this is in contrast to prospective outpatient studies, where less typical cases get diagnosed if any cough illness is subject to microbiologic investigations for B. pertussis infection. 5 to our surprise, apnea not only occurred in infants but also in several patients ≥12 months of age. Possibly, prolonged paroxysms may have been misinterpreted as apneic spells by some observers. One death (due to pneumonia) occurred in this 4-year study during which approximately 300,000 infants were born in Switzerland. this is in the same range as deaths due to pertussis in uS children, where between 10 and 20 such fatalities are reported each year and the birth cohort is approximately 4 million. 13 the high burden of pertussis raises the question about optimal prevention of pertussis in infants, especially in newborns and young infants. Of note, only a single patient in our study had a documented complete primary series and an age-appropriate pertussis immunization status. although the number and timing of doses were unknown in 6 additional patients with a positive pertussis immunization history and information on the immunization status was lacking in 2 patients, secondary vaccine failure apparently did not play a major role in this surveillance study with the great majority of patients being infants. data from our surveillance indicate that more efforts should be made towards early, timely and complete immunization in infants, as this could have a major impact on the burden of hospitalization due to pertussis in Switzerland. Possibly, switching from the current 2-4-6 month schedule (31) 28 (70) 10 (25) 12 (30) 5 (12) 1 (2) 0 (0) 2 months 28 (22) 17 (61) 7 (25) 3 (11) 6 (21) 1 (4) 0 (0) 3-5 months 26 (20) 12 (46) 7 (27) 0 (0) 2 (8) 3 (12) 0 (0) 6-11 months 13 (10) 10 (77) 3 (23) 3 (23) 3 (23) 1 (8) (61) 28 (22) 21 (16) 19 (15) 8 (6) 3 (2) *For example, grandparent, aunt/uncle and caretaker.
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to a 2-3-4 month schedule for the primary series could improve timely immunization. in fact, this schedule has been recommended in Switzerland for preterm infants (born <33 weeks of gestation) or infants with a birth weight <1500 g and, more recently, for infants who are planned to be at daycare before 5 months of age. 15 However, even with timely and complete infant immunization starting at 2 months of age, the problem of severe pertussis in young infants cannot be solved as some will contract pertussis before 2 months of age and the first 1 or 2 doses provide only partial protection as does the complete series of 3 doses 16, 17 and consecutive booster doses. 18 in this regard, direct protection of newborns by active immunization would be a logical measure. However, this concept has proven to work only with a noncommercial monovalent acellular pertussis vaccine, 19 whereas use of a conventional diphtheria-tetanusacellular pertussis combination vaccine led to disappointingly poor immune responses. 20 alternatively, maternal immunization during pregnancy may protect newborns by means of passive antibody transfer via the placenta. 21 Members from our group have demonstrated in 20 infants with PCr-confirmed pertussis at <6 months of age that their median cord blood pertussis-specific igg antibody values were lower than in 80 matched controls. 22 this study therefore supports the strategy of pertussis immunization in pregnant women.
Similar to previous reports, siblings and close adult contact persons were the main source of infection in our patients. [23] [24] [25] therefore, indirect protection by immunization of close contact persons of newborns (so-called cocoon strategy) and pregnant women appears to be an attractive alternative for or addition to direct protection of young infants. 26 Both target groups, however, are challenging with regards to implementation of immunization and its efficiency is limited 27 given that in a significant part of infants hospitalized for pertussis, the source of infection remains unknown and may be outside the "cocoon" around the infant. therefore, the recent recommendation of a dose of pertussis vaccine for adults 25-29 years of age and all close contacts to infants <6 months of age (in 2012) 10 and for all adolescents and pregnant women (in 2013) 9 in Switzerland may not be sufficient in controlling pertussis hospitalizations of infants even if high coverage will be achieved. to monitor the effects of these new recommendations, the SPSu pertussis program has been reactivated in January 2013 for a period of 4 years. this will allow us to evaluate the effects of the current pertussis immunization recommendations in the near future.
Our study has strengths and limitation. as a strength, cases were identified in a prospective and standardized national pediatric surveillance network covering all pediatric units and hospitals nationwide. Compliance with monthly reporting was 100%. Further, the great majority of cases were laboratory confirmed. However, given that PCr is not perfectly sensitive and serologic tests for B. pertussis infection were not applied in a consistent way, underdiagnosis and therefore underreporting of hospitalizations due to pertussis are likely. 28 Further, capture-recapture analysis of a different SPSu project has shown that by mistake not all diagnosed cases in the pediatric units are reported to SPSu. 29 Finally, we cannot exclude that children with pertussis were hospitalized outside the country (eg, while on vacation), but this is unlikely to be a bias of significant magnitude.
in conclusion, the great majority of pediatric patients hospitalized for pertussis were young infants. no or incomplete pertussis vaccination rather than vaccine failure explained most pertussis cases leading to hospitalization in Switzerland, and increased immunization activities at all levels of the general population are needed to prevent severe pertussis in vulnerable young infants.
